The invention relates to novel compounds of the general formula (I),

##STR00001##

with Het-2 being an optionally substituted bicyclic heteroaryl of the formula

##STR00002##

pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.

Compounds are provided that are modulators of the C5a receptor. The compounds are substituted piperidines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of C5a receptors.

Provided are a polymer medicament for treating hyperkalemia, and a preparation method thereof. Specifically, a polymer is provided, and the polymer includes repeating units obtained by polymerizing a monomer and a crosslinking agent. A molar ratio of the monomer to the crosslinking reagent ranges from 1:0.02 to 1:0.20. The monomer includes an acidic group and a pKa-reducing group next to the acidic group. The acidic group is selected from the group consisting of sulfonic acid group (—SO.sub.3—), sulfuric acid group (—OSO.sub.3—), carboxylic group (—CO.sub.2—), phosphonic acid group (—OPO.sub.3.sup.2—), phosphate group (—OPO.sub.3.sup.2—), and sulfamic acid group (—NHSO.sub.3—). The pKa-reducing group is selected from the group consisting of nitro, cyano, carbonyl, trifluoromethyl, and halogen atoms. The crosslinking agent has three or four reaction sites. The polymer can be used to treat hyperkalemia.

Disclosed is a method for treating manganese (manganese) toxicity in a subject. The method includes administering to the subject an effective amount of a hypoxia inducible factor (HIF) prolyl hydroxylase inhibitor or a pharmaceutically acceptable salt or solvate thereof.

Disclosed is a method for treating manganese (manganese) toxicity in a subject. The method includes administering to the subject an effective amount of a hypoxia inducible factor (HIF) prolyl hydroxylase inhibitor or a pharmaceutically acceptable salt or solvate thereof.

The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.

Provided herein are methods and compositions for treating nephropathic conditions such as chronic kidney disease, as well as phosphate concentration disorders and myopathy related to phosphate concentration disorders. The methods and compositions include administering a therapeutically effective amount of L-BAIBA ((S)-β-aminoisobutyric acid) to a subject in need thereof.

Provided herein are methods and compositions for treating nephropathic conditions such as chronic kidney disease, as well as phosphate concentration disorders and myopathy related to phosphate concentration disorders. The methods and compositions include administering a therapeutically effective amount of L-BAIBA ((S)-β-aminoisobutyric acid) to a subject in need thereof.

The present invention discloses oral compositions for nourishment of a mammalian subject which comprises steviol glycoside, citric acid monohydrate, monosodium glutamate and/or glycine. These compositions, being highly palatable, increase consumption of said composition, further configured to decrease mortality rate, increase weight gain, reduced use of either antibiotics or milk replacers and improve small intestine anatomy of said mammalian.

The present invention discloses oral compositions for nourishment of a mammalian subject which comprises steviol glycoside, citric acid monohydrate, monosodium glutamate and/or glycine. These compositions, being highly palatable, increase consumption of said composition, further configured to decrease mortality rate, increase weight gain, reduced use of either antibiotics or milk replacers and improve small intestine anatomy of said mammalian.